drugset / Trial / NCT04878432
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).
Timeline
- Start
- 2022-03-17
- Primary completion
- 2023-10-26
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sabatolimab | Monoclonal antibody | — | Intravenous |
| Background | ASTX727 | Unknown | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |
| Background | Decitabine | Small molecule | — | Intravenous |